Literature DB >> 19471090

MicroRNAs in diabetes: tiny players in big disease.

Amit K Pandey1, Priyanka Agarwal, Kirandeep Kaur, Malabika Datta.   

Abstract

MicroRNAs (miRNAs) are a novel group of universally present small non-coding RNAs that have been implicated in wide ranging physiological processes and thereby are critical in the manifestation of diverse diseases. Since their discovery as developmental regulators in C.elegans, they have come a long way and are currently associated with normal and diverse pathophysiological states including Parkinson's syndrome, cardiac hypertrophy, viral infection, diabetes and several types of cancer. Of special significance is their involvement in diabetes, an area in which several emerging reports point to the fact that these small RNA species could be special and critical in this complex disease and they or their specific inhibitors may be exploited as targets for therapeutic intervention. The stable nature of these miRNAs over mRNAs is an added advantage of them being projected for the same. This review focuses on and discusses the current diabetic epidemic and the potential role(s) of these miRNAs in various physiological processes that lead to the diabetic phenotype with an objective of better understanding the emerging mechanisms of these small molecules in the development and progression of diabetes and its complications. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19471090     DOI: 10.1159/000218169

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  70 in total

1.  miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis.

Authors:  Shanzhong Yang; Na Xie; Huachun Cui; Sami Banerjee; Edward Abraham; Victor J Thannickal; Gang Liu
Journal:  FASEB J       Date:  2012-06-01       Impact factor: 5.191

Review 2.  microRNAs: critical regulators in Th17 cells and players in diseases.

Authors:  Bin Wei; Gang Pei
Journal:  Cell Mol Immunol       Date:  2010-04-05       Impact factor: 11.530

3.  MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome.

Authors:  Ilias Alevizos; Stefanie Alexander; R James Turner; Gabor G Illei
Journal:  Arthritis Rheum       Date:  2011-02

4.  Role of microRNA-21 in regulating 3T3-L1 adipocyte differentiation and adiponectin expression.

Authors:  Min Kang; Li-Mei Yan; Wen-Yu Zhang; Yu-Mei Li; An-Zhou Tang; He-Sheng Ou
Journal:  Mol Biol Rep       Date:  2013-06-21       Impact factor: 2.316

5.  MicroRNAs in hepatic pathophysiology in diabetes.

Authors:  Kirandeep Kaur; Himanshi Bhatia; Malabika Datta
Journal:  World J Diabetes       Date:  2011-10-15

6.  Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling.

Authors:  Yan-Zi Yang; Xiao-Juan Zhao; Hong-Jiang Xu; Shan-Chun Wang; Ying Pan; Shui-Juan Wang; Qiang Xu; Rui-Qing Jiao; Hong-Mei Gu; Ling-Dong Kong
Journal:  Acta Pharmacol Sin       Date:  2018-12-19       Impact factor: 6.150

Review 7.  Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.

Authors:  Alieh Gholaminejad; Hossein Abdul Tehrani; Mohammad Gholami Fesharaki
Journal:  J Nephrol       Date:  2018-07-17       Impact factor: 3.902

8.  A G-quadruplex DNA-based, label-free and ultrasensitive strategy for microRNA detection.

Authors:  Li Yan; Yiyong Yan; Lei Pei; Wei Wei; Jing Zhao
Journal:  Sci Rep       Date:  2014-12-10       Impact factor: 4.379

9.  miR-145 regulates myofibroblast differentiation and lung fibrosis.

Authors:  Shanzhong Yang; Huachun Cui; Na Xie; Mert Icyuz; Sami Banerjee; Veena B Antony; Edward Abraham; Victor J Thannickal; Gang Liu
Journal:  FASEB J       Date:  2013-03-01       Impact factor: 5.191

10.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.

Authors:  Gang Liu; Arnaud Friggeri; Yanping Yang; Jadranka Milosevic; Qiang Ding; Victor J Thannickal; Naftali Kaminski; Edward Abraham
Journal:  J Exp Med       Date:  2010-07-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.